Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance

Clinical Cancer Research

Volumn 19, Issue 20, 2013, Pages 5591-5601

  De Haart, Sanne J ^a   Van De Donk, Niels W C J ^a,c   Minnema, Monique C ^a   Huang, Julie H ^a   Aarts Riemens, Tineke ^a   Bovenschen, Niels ^a   Yuan, Huipin ^b   Groen, Richard W J ^a,c   McMillin, Douglas W ^c   Jakubikova, Jana ^c   Lokhorst, Henk M ^a   Martens, Anton C ^a   Mitsiades, Constantine S ^c   Mutis, Tuna ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b XPand Biotechnology BV   (Netherlands)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 3; FAS ANTIGEN; GRANZYME B; SEPANTRONIUM BROMIDE; SHORT HAIRPIN RNA; SURVIVIN;

ACCESSORY CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BIOLUMINESCENCE; BONE MARROW; BONE MARROW CELL; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION MEDIATED IMMUNE RESISTANCE; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; STROMA CELL; SUPERNATANT; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL COMMUNICATION; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; HUMANS; IMIDAZOLES; IMMUNOMODULATION; IMMUNOTHERAPY, ADOPTIVE; MICE; MULTIPLE MYELOMA; NAPHTHOQUINONES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886437588     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3676     Document Type: Article

References (41)

1. Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC, Anderson KC. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 2007;101: 950-68.
2. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009;28:231-42.
3. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, et al. Tumor cell-specific bioluminescence platform to identify stromainduced changes to anticancer drug activity. Nat Med 2010;16:483-9.
4. McMillin DW, Delmore J, Negri J, Ooi M, Klippel S, Miduturu CV, et al. Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation. PLoS ONE 2011;6:e20226.
5. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367-75.
6. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14:2519-26.
7. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009;9:665-74.
8. Gorgun G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010;116:3227-37.
9. Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, et al. Tcell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001;98:934-9.
10. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004;103:4362-4.
11. Verdonck LF, LokhorstHM, Dekker AW,Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet 1996;347:800-1.
12. Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000;26:1179-84.
13. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003;102:1927-9.
14. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006;29:233-40.
15. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012;13:e32-e42.
16. Chouaib S, Meslin F, Thiery J, Mami-Chouaib F. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer. Clin Immunol 2009;130:34-40.
17. Begley J, Ribas A. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 2008;14:4385-91.
18. Holloway PA, Kaldenhoven N, Kok-Schoemaker HM, Dijk M, Otten HG, Tilanus M, et al. A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution. Br J Haematol 2005;128:73-81.
19. Spaapen R, van den OK, Ivanov R, Bloem A, Lokhorst H, Mutis T. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy. Clin Cancer Res 2007;13:4009-15.
20. den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998;279: 1054-7.
21. Holloway PA, Kaldenhoven N, van DM, Bloem AC, de LW, van der ZR, et al. Susceptibility of malignant plasma cells to HA-1(H) specific lysis suggests a role for the minor histocompatibility antigen HA-1 in the graft-versus-myeloma effect. Leukemia 2004;18:1543-5.
22. Hantgan RR, Endenburg SC, Sixma JJ, de Groot PG. Evidence that fibrin alpha-chain RGDX sequences are not required for platelet adhesion in flowing whole blood. Blood 1995;86:1001-9.
23. Rothen-Rutishauser BM, Kiama SG, Gehr P. A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. Am J Respir Cell Mol Biol 2005;32:281-9.
24. Takagi M, Horii K, Yoshida T. Effect of pore diameter of a porous membrane on progenitor cell content during membrane-separated coculture of hematopoietic cells and a stromal cell line. J Artif Organs 2003;6:130-7.
25. Groen RW, Noort WA, Raymakers RA, Prins HJ, Aalders L, Hofhuis FM, et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 2012;120:e9-e16.
26. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
27. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996;12:697-715.
28. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002;2:735-47.
29. Berke G. The CTL's kiss of death. Cell 1995;81:9-12.
30. Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 2008;180:163-70.
31. Sutton VR, Davis JE, Cancilla M, Johnstone RW, Ruefli AA, Sedelies K, et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med 2000;192:1403-14.
32. Wang X, Zhang Z, Yao C. Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells. Leuk Res 2010;34:1325-9.
33. Tang H, Shao H, Yu C, Hou J. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. Biochem Pharmacol 2011;82:1066-72.
34. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12: 269-81.
35. Hazlehurst LA, Landowski TH, Dalton WS. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 2003;22:7396-402.
36. Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, et al. Angiogenesis in multiple myeloma. Eur J Cancer 2006;42:1581-90.
37. Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006;25:4257-66.
38. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23:10-24.
39. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93: 1658-67.
40. Mace PD, Shirley S, Day CL. Assembling the building blocks: structure and function of inhibitor of apoptosis proteins. Cell Death Differ 2010;17:46-53.
41. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.